Navigation Links
Pivotal Phase 3 Data from Boehringer Ingelheim Hepatitis C Portfolio to be Presented at 64th Annual AASLD Meeting
Date:10/1/2013

ster Hall Interferon-Free Treatment with

Faldaprevir, Deleobuvir (BI 207127)

and Ribavirin in SOUND-C3: 95% SVR12

in HCV-GT1b

J.F. Dufour

ID# 1102
Session: HCV Therapeutics: New
Agents
Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall STARTVerso 4 Phase III trial of

faldaprevir plus peg interferon alfa-2a

and ribavirin (PR) in patients with HIV

and HCV genotype 1 coinfection:

end of treatment response

J. Rockstroh

ID# 1099
Session: HCV Therapeutics: New
Agents
Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall Pharmacokinetic interactions of

Faldaprevir and Deleobuvir (BI 207127)

and their individual and combined effect on

selected cytochrome P450 (CYP) probe

substrates in genotype 1 hepatitis C

infected patients

C. Cooper

ID# 1083
Session: HCV Therapeutics: New
Agents
Date: Sun, Nov. 3
Time: 8:00 AM – 5:30 PM ET
Location: Poster Hall About Boehringer Ingelheim in Hepatitis C Virus (HCV)
In partnership with the scientific community, our clinical trial program is rigorously designed to find answers to the challenges that HCV patients face, including those who are the most difficult to treat. Our pivotal HCV clinical trials for faldaprevir and deleobuvir are comprised of two multi-trial programs, STARTVerso and HCVerso®.

Faldaprevir, also known as BI 201335, is an investigational, oral protease inhibitor that is specifically designed to target viral replication in the liver. Boehringer Ingelheim is developing faldaprevir as a core component of both interferon-based and interferon-free hepatitis C treatment regimens. STARTVerso is a multi-study Phase 3 trial program that evaluates faldaprevir combined with PegIFN/RBV. The four trials that make up this program study
'/>"/>

SOURCE Boehringer Ingelheim
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. EntreMed Initiates Crossover Bioavailability And Food Effect Study Of ENMD-2076 Dosage Form To Be Used For Pivotal/Registration Clinical Trials
2. Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
3. CSL Behring Doses First Patient in Part 3 of Global Phase I/III Pivotal Study of rVIII-SingleChain (Recombinant Single-Chain Factor VIII) for Treatment of Hemophilia A
4. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
5. Sanofi Reports Positive Topline Results from Pivotal Phase III JAKARTA Study for JAK2 Inhibitor in Myelofibrosis
6. Relievant Medsystems Achieves Completion of Interim Safety Data Analysis of Intracept in SMART Pivotal Study and Expands Senior Leadership Team
7. Boehringer Ingelheim to Announce Pivotal Phase 3 Hepatitis C Data at the International Liver Congress
8. Venaxis Advances Pivotal U.S. Study and Accelerates European Market Development for APPY1 Blood-based Appendicitis Test
9. AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
10. First U.S. Patients Treated in PneumRx RENEW Pivotal Study for Treatment of Severe Emphysema
11. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 2014 Reportlinker.com announces that a new ... catalogue: Insulin Pump ... http://www.reportlinker.com/p01957812/Insulin-Pump-Market--Forecast-–-Worldwide-Analysis.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Equipment_and_Supply ... Insulin Pumps are gaining strong acceptance ...
(Date:1/15/2014)... , Jan. 15, 2014  Zafgen, Inc., a leading ... of severely obese patients, today announced initial results ... selective inhibitor of methionine aminopeptidase 2 (MetAP2), in ... of genetic obesity.  These results showed improvements in ...
(Date:1/14/2014)... Brandeis Medical Center, led by Dr. Emmanuel Brandeis , offers ... tattoo removal experience with the advanced Astanza Duality laser and a ... cosmetic services with cutting edge medical technology and offering expert medical ... has seen a dramatic increase in the presence of tattoo ...
Breaking Medicine Technology:Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Beverly Hills Physician Features Tattoo Removal with the Astanza Duality Laser, Offers $99 Special 2
... , , , , , BEIJING ... SVA),a leading China -based vaccine manufacturer, today announced that it ... of the,company in an underwritten public offering. Sinovac plans to grant ... shares,to cover overallotments. , Sinovac plans to ...
... , SAN DIEGO , Jan. 20, 2010 Amylin ... Call for the fourth quarter and full year 2009 on Wednesday, ... PT . Daniel M. Bradbury , Amylin,s president and chief executive ... release financial results for the fourth quarter and year ended December ...
Cached Medicine Technology:Sinovac Announces Plan to Launch Offering of Common Shares 2Sinovac Announces Plan to Launch Offering of Common Shares 3Amylin Pharmaceuticals to Webcast Year-End Financial Results 2
(Date:4/17/2014)... University School of Medicine (BUSM) have discovered that ... an experimental model. The findings, reported in the ... , may lead to more effective treatments for ... of the leading causes of illness and death ... impact by limiting the productivity of workers and ...
(Date:4/17/2014)... off depression among retirees, particularly among those who live ... The Journals of Gerontology, Series B: Psychological Sciences and ... Use and Depression Among Retired Older Adults in the ... that Internet use reduced the probability of a depressed ... , Late-life depression affects between 5 and 10 million ...
(Date:4/17/2014)... days to find a colored ribbon representing a disease. A ... what color ribbon does one think of with lung cancer?, ... many suffering from the disease, black may be the only ... of lung cancer patients, primarily smokers between the ages of ... the stigma often felt by these patients, the emotional toll ...
(Date:4/17/2014)... is less than 40 years away from a food ... governments, according to a top scientist at the U.S. ... human history, food production will be limited on a ... energy," said Dr. Fred Davies, senior science advisor for ... become as politically destabilizing by 2050 as energy issues ...
(Date:4/17/2014)... they suffer a cardiac arrest outside of a hospital ... to new research conducted at St. Michael,s Hospital. , ... arrest get adrenaline, which has been the drug recommended ... Lin, an emergency physician and trauma team leader at ... survival rates of patients who suffer a cardiac outside ...
Breaking Medicine News(10 mins):Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Internet use may cut retirees' depression 2Health News:Unraveling the 'black ribbon' around lung cancer 2Health News:Food shortages could be most critical world issue by mid-century 2Health News:Adrenaline does little to increase patient's survival after cardiac arrest 2
... 1 (HealthDay News) -- Black and Hispanic children with frequent ... care than white children, say U.S. researchers. They analyzed ... and found that each year about 4.6 million children have ... 12 months. Overall, 3.7 percent of children with frequent ...
... Alexandria, VA Racial and ethnic disparities among children with ... according to new research published in the November 2010 issue ... Ear infections are one of the most common health ... by their third birthday. Annual costs in the United States ...
... lacked a reliable screening test for it. Now researchers at ... report the PHQ-9 (Patient Health Questionnaire - 9 item) is ... Led by Laura P. Richardson, MD, MPH, the team ... 442 teenage patients, age 13-17, at Group Health. The test ...
... have developed an efficient method for extracting and archiving ... keep track of estimated radiation dose delivered to each ... informed health care decisions and improve patient safety, according ... Journal of the American College of Radiology ( www.jacr.org ...
... to designing effective drug treatments that are precisely tailored to ... any of which can trigger the body,s immune system defenses. ... the latest issue of Nature Medicine online Oct. ... three weeks can pinpoint the unique binding site or ...
... Hepatitis C patients who receive a liver from a white ... receive a liver from a black donor, researchers have found. ... a liver from a white donor, the study authors noted. ... 165 hepatitis C patients who received a liver transplant at ...
Cached Medicine News:Health News:Race, Income Affect Care for Ear Infections: Study 2Health News:Racial and ethnic disparities impact care for children with frequent ear infections 2Health News:Racial and ethnic disparities impact care for children with frequent ear infections 3Health News:Researchers develop successful method for extracting and archiving patient radiation dose info 2Health News:Immune system's bare essentials used to speedily detect drug targets 2Health News:Immune system's bare essentials used to speedily detect drug targets 3
Our smallest port is available with or without a COOK Peel-Away Introducer Set....
The mid-sized polysulfone is about 3/4 the diameter and half the weight of the standard model. The silicone catheter has an I.D. of 0.9 mm....
The WaveMap provides immediate clinical decision making information with automatic calculation of pressure gradients and FFR measurements.,SmartWire Pressure Guide Wire - The intelligent choice in ...
Used for vascular access. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: